SCHEMBL12203151

SCHEMBL12203151

CC(C)(C)NC(=O)Nc1cc(C(C)(C)C)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
TP53 P04637 3/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MAPK1 P28482 3/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
ANO1 Q5XXA6 3/20 0.44
NR3C2 P08235 1/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12203066 0.86 GCK (0.54) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL12461221 0.83 NPC1 (0.58) SMN1; SMN2NPC1RAB9ATP53KDM4E
SCHEMBL84506 0.82 L3MBTL1 (0.52) KDRBRAF
SCHEMBL2635471 0.82 NR3C2 (0.47) SMN1; SMN2NPC1RAB9ATP53KDM4E
SCHEMBL12203143 0.82 NR3C2 (0.40) SMN1; SMN2NPC1RAB9ATP53GAA
SCHEMBL12203144 0.82 JAK2 (0.52) SMN1; SMN2ALDH1A1MAPK1KMT2ANR3C2
SCHEMBL5029364 0.81 NR3C2 (0.59) NR3C2
SCHEMBL12203072 0.80 MAPK1 (0.47) SMN1; SMN2NPC1RAB9ATP53MAPK1
SCHEMBL12203075 0.80 MAPK1 (0.47) SMN1; SMN2NPC1RAB9ATP53KDM4E
SCHEMBL12203146 0.80 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 SMN1; SMN2 4242/4885NPC1 2834/4885RAB9A 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.